on AMOEBA (EPA:ALMIB)
Amoéba Poised for Growth Amid Significant 2024 Milestones
In 2024, Amoéba achieved significant milestones in biocontrol and cosmetics. The signing of a Memorandum of Understanding with Koppert and positive EFSA conclusions have advanced its biocontrol active substance. This paves the way for the commercialisation of its product "AXPERA" slated for late 2025 or early 2026.
Financially, Amoéba showed a notable improvement in 2024, with a reduced net loss of -€6,592k compared to -€14,298k in 2023. This improvement is attributed to stricter cost management and a strategic shift towards commercialisation. Shareholder confidence is evident with Nice & Green’s continued financial support.
In 2025, Amoéba focuses on finalising regulatory approvals and increasing production capacity. Its position in both the European and U.S. markets will be strengthened through these efforts, marking a pivotal shift towards becoming a fully industrialised and commercial entity.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all AMOEBA news